A new cancer treatment approach has shown potential in improving survival rates. High-risk melanoma patients were involved in a large trial. The trial's outcome is a significant development.

Merck and Moderna made an announcement about the trial's success. Further information about the trial is available. The treatment in question is a personalized vaccine based on mRNA technology.

Details about the trial and its results can be found through the companies' announcement.